Video
Dr. Bekaii-Saab Discusses QoL With Regorafenib Dose Escalation in mCRC
Author(s):
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the quality of life findings for a dose-escalation study of regorafenib (Stivarga) in metastatic colorectal cancer.
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the quality of life (QoL) findings for a dose-escalation study of regorafenib (Stivarga) in metastatic colorectal cancer (CRC).
The phase II regorafenib dose optimization study (ReDOS) randomized patients with mCRC to either the dose-escalation arm, which began at 80 mg per day and increased weekly up to 160 mg per day if no significant drug-related toxicities occurred, or the standard dose of 160 mg of regorafenib daily. This weekly dose-escalation strategy was shown to be superior to the previous standard starting dose of 160 mg.
Bekaii-Saab says that one of the most interesting findings was regarding the QoL of the patients on this study. There was no compromise in QoL of the patients on the dose-escalation arm, but those who began at the starting dose of 160 mg, there was a drop in QoL. Ultimately, the dose-escalation may confer a larger benefit, and could perhaps change the standard, Bekaii-Saab says.
